曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌

目的探讨曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌的疗效和不良反应。方法采用随机对照实验,治疗组21例,对照组22例,对象均为HER2阳性的转移性乳腺癌患者。对照组仅给予多西他赛化疗,治疗组给予曲妥珠单抗联合多西他赛方案化疗。结果治疗组有效率为71.4%(15/21),对照组为31.8%(7/22),两组比较,差异有统计学意义(P<0.05)。两组不良反应发生情况无明显差异。结论曲妥珠单抗联合多西他赛是转移性乳腺癌的有效安全的治疗方案。

Effect of trasuzumab combined with docetaxel on metastatic breast cancer with Her2-positive

Objective To evaluate the efficacy and safety of trasuzumab combined with docetaxel as salvage therapy in metastatic breast cancer with Her2-positive. Methods Patients of metastatic breast cancer with Her2-positive were randomly divided into trial group( 21 patients) and control group( 22 patients) . Chemotherapy with docetaxel was given to all the patients. Meanwhile,Trastuzumab was given on the chemotherapy cycle in trial group as well as control patients received chemotherapy alone. Results The response rate was 71. 4% ( 15 /21) in trial group and 31. 8% ( 7 /22) in control group( P < 0. 05) . The adverse effects related to trastuzumab were mild and did not need any treatment. Conclusion Trastuzumab combined with docetaxel is effective and safe for patients with refractory metastatic breast cancer.